Proposals for Next Classification Schema of Myeloid Neoplasms
School of Public Health and Health Sciences
Health Informatics And Implementation Science
Biostatistics And Health Services Research
Cutler Chair in Vascular and Endovascular Surgery
Donna M. and Robert J. Manning Chair in Obstetrics and Gynecology
Melvin S. and Sandra L. Cutler Chair in Biomedical Research
Dr. Henninger is a vascular neurologist with research interest in the neurobiology of axonal injury associated with traumatic brain injury and its contribution to functional outcome.
The Castilla laboratory is accepting applications for postdoctoral positions. The candidates should be close to or have recently graduated with a Ph.D. or M.D./Ph.D. degree (within 1 year) in the fields of Cancer Biology, Genetics, Biochemistry, Cell Biology or related field. The candidates must also have a proven track record of productivity and research experience. Previous experience using immunocompromised and transgenic mice, in vitro and in vivo assays with small molecules or nanoparticles, or hematopoietic stem cells is preferred. We are looking for highly motivated candidates with excellent communication skills, and able to work independently and in cooperation with other members of the laboratory. Applicants should send their CV, a cover letter summarizing background and research interests, and three letters of references by electronic mail to: Dr. Lucio H. Castilla, Associate Professor University of Massachusetts Medical School Lucio.Castilla@umassmed.edu
Potential Rotation Projects<?xml:namespace prefix = u5 /><u5:p></u5:p><?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" /><o:p></o:p> <u5:p> </u5:p><o:p></o:p> 1. Role of core binding factors on hematopoietic stem cell function and survival. We use molecular pharmacologic and functional approaches to study the role of the RUNX factors in self renewal and proliferation of hematopoietic stem and progenitor cells, using genetically modified mice and human progenitor cells. <u5:p></u5:p><o:p></o:p> <u5:p> </u5:p><o:p></o:p> 2. Study the molecular mechanism of leukemia initiation and maintenance. Transcription factors and components of cytokine signaling are frequently mutated in human cancer, including leukemia. These mutations deregulate the proliferation, differentiation and survival of hematopoietic stem cells. We study the role of members of RUNX and RAS protein families in the function of hematopoietic stem cell function, pre-leukemic progenitors, and leukemia-initiating cells. <u5:p></u5:p><o:p></o:p> <u5:p> </u5:p><o:p></o:p> 3. Translational research: Recent evidence suggests that inhibition of pathways activated by gene mutations can be used to eliminate leukemia cells, and not affecting normal cells. We use small molecule inhibitors of leukemia oncogenes to test whether repression of activated pathways hinder survival of leukemia initiating cells, and eliminate leukemia. We use a combination of mouse models and human leukemia cells to test the efficacy, specificity and toxicity of candidate inhibitors, as single agents or in combination with first line leukemia drugs.<u5:p></u5:p><o:p></o:p>
Imoigele P. Aisiku, MD’97 Chair in Health Equity and Diversity
Barbara Helen Smith Chair in Preventive & Behavioral Medicine
Richard M. Haidack Professor in Medicine
Dr. John Meyers Professor in Primary Care Medicine
Population and Quantitative Health Sciences
UMass Worcester Prevention Research Center
Prevention Research Center at UMass Chan
Tweets by @DrSherryPagoto
Healthcare Delivery and Population Sciences at UMass Chan - Baystate
Preventing Osteoarthritis After an ACL Injury
Preventing Osteoarthritis After an ACL Injury Playing the Long Game: Consensus for Preventing OA
Preventing Osteoarthritis After an ACL Injury Playing the Long Game: Consensus for Preventing OA Characteristics of Accelerated Hand Osteoarthritis
Pediatric Immunology & Infectious Disease
Joseph D. Early Chair in Biomedical Research
Prevention Strategies for Second Primary Malignancies After CAR-T Therapy
The Darkest Side of AML: The TP53 Mutation
Clonal Hematopoiesis in Clinical Practice: Real-World Insights
Unpacking CHIP: Recent Updates, Remaining Questions
Dr Patel on the Impact of Donor-Engrafted Clonal Hematopoiesis on Outcomes With Auto-/Allo-HSCT
Effects of donor-engrafted clonal hematopoiesis in stem cell transplantation
High-Risk Myelodysplastic Syndrome Findings in the SELECT-MDS-1 Study
Stem Cell Transplantation: How Clonal Hematopoiesis Shapes Patient Outcomes
Olutasidenib as a Breakthrough for R/R mIDH1 AML Patients
The Impact of Mutations in Clonal Hematopoiesis
TP53 in MDS & AML Prognostication & Treatment Strategies
Exploring the Biological Basis of TP53-Aberrant MDS & AML
Improving Outcomes in Blast Phase Chronic Myeloid Leukemia
ASH Clinical News - Practical Solutions Amid Cuts to Federally Funded Research
OncLive with Dr. Patel and Dr. Gerber: p53 Immunohistochemistry
Early Identification of TP53-Mutant MDS and AML Using p53 Immunostaining
Point-of-Care p53 IHC Unveils TP53-Mutant MDS/AML
IHC Enables Rapid Identification of TP53-Mutant MDS/AML
ASH Clinical News: p53 Immunohistochemistry for TP53-Mutant MDS/AML
p53 Immunostain in TP53-Mutant MDS and AML